<DOC>
	<DOCNO>NCT00996723</DOCNO>
	<brief_summary>This Phase I clinical trial evaluate combination vandetanib dasatinib radiation therapy ( RT ) child newly diagnose diffuse intrinsic pontine glioma ( DIPG ) .</brief_summary>
	<brief_title>Clinical Trial Evaluating Combination Vandetanib Dasatinib During After Radiation Therapy ( RT ) Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma ( DIPG )</brief_title>
	<detailed_description>This trial estimate maximum safe dose vandetanib dasatinib administer 6 week local RT child newly diagnose DIPG .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Age must ≥ 18 month &lt; 21 year 2 . Diagnosis DIPG highgrade glioma originate brainstem . 3 . Lansky ( research participant ≤ 16 year ) Karnofsky ( research participant &gt; 16 year ) performance score ≥ 40 time study enrollment 4 . Adequate organ function time study enrollment follow : Bone marrow : ANC ≥ 1,000/μL , platelet count ≥ 100,000/μL ( transfusion independent ) , hemoglobin concentration ≥ 8g/dL ( may transfuse ) Renal : Serum creatinine concentration &lt; 2x institutional normal value age GFR &gt; 70ml/min/1.73m2 Hepatic : Total bilirubin concentration &lt; 1.5x institutional upper limit normal age ; SGPT &lt; 5x institutional upper limit normal ; albumin ≥ 2 g/dL 5 . Electrocardiogram ( EKG ) average QTc interval &lt; 450 msec . If research participant QTc interval ≥ 450 msec screen EKG , screen EKG may repeat twice ( least 24 hour apart ) . The average QTc interval three screen EKGs must &lt; 450 msec order research participant eligible study . Research participants abnormal serum electrolytes QTc interval ≥ 450 msec repeat EKG repeat concentration serum electrolyte correct 6 . Female research participant childbearing age must pregnant ( confirm serum urine pregnancy test within 1 week treatment start ) breastfeeding . 7 . Female research participant childbearing age male research participant child father potential must agree use safe contraceptive method 1 . Metastatic disease 2 . Use enzymeinducing anticonvulsant 3 . Research participant receive type anticancer treatment 4 . Research participant uncontrolled infection 5 . Research participant concomitant significant medical illness investigator 's opinion adequately control appropriate therapy , would impair evaluation side effect related treatment , alter drug metabolism tolerance treatment 6 . QTc interval prolongation medication require discontinuation medication 7 . Research participant history cardiac arrhythmia congenital long QT syndrome 8 . Use concomitant medication may cause QT interval prolongation and/or induce Torsades de Pointes 9 . Hypertension define systolic and/or diastolic blood pressure &gt; 95th percentile age , height gender , blood pressure &gt; 140/90 research participant ≥ 18 year age . If hypertension detect , blood pressure value &lt; 95th two separate occasion need document registration . Body surface ≥ 1.8m2 research participant enrol dosage level 2 , 3 , 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>